|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
108,674,000 |
Market
Cap: |
42.88(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2298 - $2.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 707 |
Guru Rank Value : 1.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
4 |
4 |
Total Shares Sold |
211,204 |
267,396 |
419,842 |
591,605 |
Total Sell Value |
$130,313 |
$170,773 |
$340,560 |
$980,941 |
Total People Sold |
5 |
5 |
6 |
9 |
Total Sell Transactions |
5 |
10 |
23 |
41 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Heiden William K |
|
|
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
52,000 |
|
- |
|
Gallagher Carol Giltner |
|
|
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
132,418 |
|
- |
|
Seidenberg Beth C |
|
|
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
58,689 |
|
- |
|
Dobmeier Eric |
|
|
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
59,500 |
|
- |
|
Renaud Ronald C Jr |
|
|
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,500 |
31,500 |
|
- |
|
Koppikar Utpal |
Chief Financial Officer |
|
2022-06-08 |
4 |
AS |
$5.63 |
$32,952 |
D/D |
(5,853) |
203,529 |
|
-30% |
|
Koppikar Utpal |
Chief Financial Officer |
|
2022-05-17 |
4 |
AS |
$5.32 |
$29,675 |
D/D |
(5,582) |
207,592 |
|
-40% |
|
Touchon Pascal |
President and CEO |
|
2022-05-17 |
4 |
AS |
$5.32 |
$73,962 |
D/D |
(13,913) |
486,313 |
|
-40% |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-05-17 |
4 |
AS |
$5.32 |
$20,597 |
D/D |
(3,873) |
163,006 |
|
-40% |
|
Murugan Amar |
SVP, GC & Secretary |
|
2022-05-17 |
4 |
AS |
$5.32 |
$17,134 |
D/D |
(3,223) |
133,735 |
|
-40% |
|
Koppikar Utpal |
Chief Financial Officer |
|
2022-03-01 |
4 |
AS |
$9.86 |
$37,090 |
D/D |
(3,763) |
213,174 |
|
-28% |
|
Koppikar Utpal |
Chief Financial Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
61,235 |
216,937 |
|
- |
|
Yarema Kristin |
Chief Commercial Officer |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,533 |
171,415 |
|
- |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-03-01 |
4 |
AS |
$9.86 |
$21,890 |
D/D |
(2,221) |
166,879 |
|
-28% |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
78,506 |
169,100 |
|
- |
|
Murugan Amar |
SVP, GC & Secretary |
|
2022-03-01 |
4 |
AS |
$9.86 |
$25,400 |
D/D |
(2,577) |
136,958 |
|
-28% |
|
Murugan Amar |
SVP, GC & Secretary |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
51,814 |
139,535 |
|
- |
|
Touchon Pascal |
President and CEO |
|
2022-03-01 |
4 |
AS |
$9.86 |
$87,009 |
D/D |
(8,828) |
500,226 |
|
-28% |
|
Touchon Pascal |
President and CEO |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
180,565 |
509,054 |
|
- |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-02-10 |
4 |
AS |
$16.00 |
$80,000 |
D/D |
(5,000) |
90,594 |
|
-55% |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-02-10 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
95,594 |
|
- |
|
Koppikar Utpal |
Chief Financial Officer |
|
2022-02-07 |
4 |
AS |
$14.46 |
$36,096 |
D/D |
(2,496) |
155,702 |
|
-67% |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-01-03 |
4 |
AS |
$16.01 |
$80,050 |
D/D |
(5,000) |
90,594 |
|
-69% |
|
Dupont Jakob |
EVP, Head of R&D |
|
2022-01-03 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
95,594 |
|
- |
|
Dupont Jakob |
EVP, Head of R&D |
|
2021-12-01 |
4 |
AS |
$17.94 |
$89,689 |
D/D |
(5,000) |
90,594 |
|
-52% |
|
736 Records found
|
|
Page 4 of 30 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|